Pan Hongming, Sun Hao, Zuo Yanjiao, Zhao Ruihu, Xue Yingwei, Song Hongjiang
Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, 150 Haping Road, Nangang District, Harbin, Heilongjiang, 150081, China.
Department of Breast Surgery, Sixth Affiliated Hospital of Harbin Medical University, Harbin, 150023, China.
BMC Cancer. 2025 Feb 27;25(1):359. doi: 10.1186/s12885-025-13715-x.
This study aimed to establish a prealbumin (PALB)-CD19 index that combines nutritional and immune statuses to comprehensively evaluate the prognosis of GC patients undergoing surgery.
A total of 389 patients who were diagnosed with GC and who underwent surgical procedures at our institution between January 2016 and December 2020 were included in this study. Among them, 97 patients underwent subtotal gastrectomy, 271 underwent total gastrectomy, and 21 underwent palliative resection. The PALB-CD19 index was developed using Cox regression analysis and regression coefficients, and LASSO regression analysis was employed to eliminate multicollinearity. Receiver operating characteristic (ROC) curves were used to calculate optimal cut-off values, and the prognostic value of different indices was compared using the area under the curve (AUC). Cox regression analysis was further utilized to identify independent prognostic factors. Survival analysis was conducted to explore differences in progression-free survival (PFS) and overall survival (OS) among patient groups. Finally, the prognostic significance of relevant factors was validated using a nomogram.
This study included 389 patients, 276 males and 113 females, with a mean age of 59.10 ± 10.19 years. Cox analysis identified PALB and CD19 as significant factors influencing survival, forming the basis for the PALB-CD19 index. The cut-off values for PALB and CD19 were determined to be 230.50 mg/L and 15.40%, respectively. Cox regression analysis confirmed that the PALB-CD19 index was an independent prognostic factor for both PFS and OS. Survival analysis demonstrated that patients with a lower PALB-CD19 index had significantly shorter PFS and OS (χ² = 45.54, P < 0.001; χ² = 47.69, P < 0.001). Subgroup analysis across different TNM stages further validated the prognostic value of the PALB-CD19 index (all P < 0.05). Nomograms incorporating the PALB-CD19 index showed high accuracy, with concordance indices (C-index) in the training and validation cohorts approaching or exceeding 0.8.
The PALB-CD19 index exhibits potential prognostic value in predicting surgical outcomes in GC patients. Its ability to integrate nutritional and immune parameters may provide clinicians with a novel and comprehensive tool for identifying high-risk patients and guiding personalized treatment strategies.
本研究旨在建立一种结合营养和免疫状态的前白蛋白(PALB)-CD19指数,以全面评估接受手术的胃癌患者的预后。
本研究纳入了2016年1月至2020年12月期间在我院诊断为胃癌并接受手术的389例患者。其中,97例行胃次全切除术,271例行全胃切除术,21例行姑息性切除术。使用Cox回归分析和回归系数建立PALB-CD19指数,并采用LASSO回归分析消除多重共线性。采用受试者工作特征(ROC)曲线计算最佳截断值,并使用曲线下面积(AUC)比较不同指数的预后价值。进一步利用Cox回归分析确定独立预后因素。进行生存分析以探讨患者组之间无进展生存期(PFS)和总生存期(OS)的差异。最后,使用列线图验证相关因素的预后意义。
本研究纳入389例患者,其中男性276例,女性113例,平均年龄59.10±10.19岁。Cox分析确定PALB和CD19是影响生存的重要因素,构成了PALB-CD19指数的基础。PALB和CD19的截断值分别确定为230.50mg/L和15.40%。Cox回归分析证实,PALB-CD19指数是PFS和OS的独立预后因素。生存分析表明,PALB-CD19指数较低的患者PFS和OS显著缩短(χ² = 45.54,P < 0.001;χ² = 47.69,P < 0.001)。不同TNM分期的亚组分析进一步验证了PALB-CD19指数的预后价值(所有P < 0.05)。纳入PALB-CD19指数的列线图显示出较高的准确性,训练和验证队列中的一致性指数(C指数)接近或超过0.8。
PALB-CD19指数在预测胃癌患者手术结局方面具有潜在的预后价值。其整合营养和免疫参数的能力可能为临床医生提供一种新颖且全面的工具,用于识别高危患者并指导个性化治疗策略。